Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: Mar 26, 2026

Modeling Ovarian Cancer Multicellular Spheroid Behavior in a Dynamic 3D Peritoneal Microdevice

Modeling Ovarian Cancer Multicellular Spheroid Behavior in a Dynamic 3D Peritoneal Microdevice

Published on: February 18, 2017

Treatment principles for peritoneal surface malignancies.

Marcello Deraco¹, Shigeki Kusamura, Carlo Corbellini

¹Peritoneal Malignancy Program, IRCCS Istituto Nazionale Tumori Foundation, Milan, Italy - marcello.deraco@istitutotumouri.mi.it.

Minerva Chirurgica

|February 6, 2016

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

FASN for diffuse malignant peritoneal mesothelioma: a prognostic biomarker after CRS+HIPEC and a therapeutic target.

Journal of translational medicine·2026

Same author

Communication skill training in surgical residency: insights from Y-SICO (Young-Italian Society of Surgical Oncology).

Updates in surgery·2026

Same author

Principles of cytoreductive surgery for primary and metastatic peritoneal malignancies-the PSOGI-ESGO-ISSPP Lyon consensus.

The Lancet. Oncology·2026

Same author

ASO Visual Abstract: MORPHology and Inter-Observer Variation in Peritoneal Disease Assessment Among Expert Peritoneal Malignancy SUrgeonS-The MORPHEUS Study.

Annals of surgical oncology·2026

Same author

Correction: MORPHology and Inter-observer Variation in Peritoneal Disease Assessment Among Expert Peritoneal Malignancy SUrgeonS: The MORPHEUS study.

Annals of surgical oncology·2026

Same author

MORPHology and Inter-observer Variation in Peritoneal Disease Assessment Among Expert Peritoneal Malignancy SUrgeonS: The MORPHEUS study.

Annals of surgical oncology·2026

Peritoneal surface malignancies (PSM) are now treatable with cytoreductive surgery (CRS) and intraperitoneal chemotherapy. This combined approach offers improved survival for selected patients with PSM, shifting management paradigms.

Area of Science:

Oncology
Surgical Oncology
Gastroenterology

Background:

Peritoneal surface malignancies (PSM) were historically considered end-stage, palliative conditions.
Recent advances recognize PSM as local-regional diseases potentially curable with aggressive treatment.
Understanding disease progression has led to novel therapeutic strategies.

Purpose of the Study:

To review the rationale and evidence for comprehensive PSM treatment.
To describe the biology of peritoneal tumor dissemination.
To detail cytoreductive surgery (CRS) and intraperitoneal chemotherapy techniques.

Main Methods:

Review of the biology and pathophysiology of peritoneal tumor dissemination.
Description of cytoreductive surgery (CRS) and intraperitoneal chemotherapy administration.

More Related Videos

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines

Published on: April 21, 2022

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

Related Experiment Videos

Last Updated: Mar 26, 2026

Modeling Ovarian Cancer Multicellular Spheroid Behavior in a Dynamic 3D Peritoneal Microdevice

Modeling Ovarian Cancer Multicellular Spheroid Behavior in a Dynamic 3D Peritoneal Microdevice

Published on: February 18, 2017

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines

Published on: April 21, 2022

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

Discussion of controversial issues in PSM management and institutional technical variants.

Presentation of recent literature on patient selection and indications.

Overview of treatment results and long-term outcomes.

Main Results:

Cytoreductive surgery (CRS) combined with perioperative intraperitoneal chemotherapy shows survival benefits over historical controls.
This comprehensive treatment is increasingly accepted as standard care for select PSM patients.
Data on patient selection, indications, and outcomes for CRS and HIPEC are presented.

Conclusions:

A paradigm shift in PSM management favors aggressive, potentially curative therapies.
Comprehensive treatment involving CRS and intraperitoneal chemotherapy offers improved survival for selected patients.
Further research and standardized protocols are essential for optimizing PSM treatment outcomes.